Technology | October 17, 2011

SenoBright Contrast Enhanced Spectral Mammography, Breast Cancer Diagnosis Gets 510(k) Clearance

October 17, 2011 GE Healthcare announced that the U.S. Food and Drug Administration (FDA) gave 510(k) clearance of an innovative technology to aid the physician in breast cancer diagnosis. GE estimates that by 2020, more than 1 million women worldwide will be examined using SenoBright, and this technology can help lead to more productive diagnosis paths for nearly 250,000 women.

GE Healthcare’s new SenoBright contrast-enhanced spectral mammography (CESM) technology is designed to produce contrast-enhanced images of the breast using a legally approved X-ray contrast agent and a dual energy acquisition technique. Launched in 2010, SenoBright is already in use at 17 major mammography centers in France, Spain, Italy, Belgium, Germany, Austria and Japan.

SenoBright uses X-rays at multiple energies to create two separate but almost simultaneous exposures. The resulting images specifically illuminate and highlight areas of iodinated contrast.

“CESM presents two images per mammographic view, one that looks like standard mammography and a second image that showed the contrast-enhanced areas that can help localize a lesion. As the images are familiar, it can therefore be easily reviewed by surgeons and oncologists. Moreover, in terms of workflow, a CESM exam takes from 5 to 10 minutes," said Clarisse Dromain, M.D. Gustave Roussy Cancer Institute, France.

The diagnostic challenge

“Worldwide, more than 1.2 million people annually are diagnosed with breast cancer. Since 1965, GE Healthcare has made significant progress in providing solutions for breast cancer detection and diagnosis that really bring a change to people’s lives. Today through ‘healthymagination,’ we continuously develop innovations to reduce costs, increase access and improve quality and efficiency of healthcare delivery around the globe,” said Anne LeGrand, GE Healthcare’s vice president and general manager of the company’s global X-ray business.

Clarity of results

Digital mammography is considered a relevant means of breast cancer screening, delivering proven clinical outcomes. The sensitivity and specificity of images can, however, be affected by a range of factors. Dense breast tissue can overlap with lesions, which are not always visible on an X-ray, and radiologists’ interpretation of images can vary. Inconclusive digital mammography presents a range of challenges to healthcare professionals and patients. Ambiguity can result in diagnostic error.

Same staff, same equipment— same day

SenoBright is intended to allow for a procedure to be conducted by the same staff, using the same mammography equipment, potentially on the same day as a traditional screening exam, thereby helping medical professionals to cut the critical time patients often have to wait from detection to diagnosis. GE Healthcare estimates that 2,500 digital mammography systems upgradeable to SenoBright are in clinical use today – delivering an excellent investment for these customers-- and providing added functionality to an existing and vital tool.

CESM technology is intended to work as an upgrade to GE Healthcare’s Senographe DS and Senographe Essential digital mammography equipment. GE’s Senographe platforms are full-field digital mammography systems designed to meet a wide range of clinical needs, from screening to diagnostic and interventional procedures.

For more information: www.gehealthcare.com

 

Related Content

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
Sponsored Content | Videos | Radiology Imaging | June 13, 2019
In an interview with itnTV, Henry Izawa, vice president, modality solutions and clinical affairs, Fujifilm Medical Sy
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Three Palm Software Releases WorkstationOne Version 1.8.8
Technology | Mammography Reporting Software | June 12, 2019
Three Palm Software announced the release of the 1.8.8 version of its breast imaging workstation, WorkstationOne. This...
Volpara Health Technologies to Acquire MRS Systems Inc.
News | Mammography Reporting Software | June 04, 2019
Volpara Health Technologies, Volpara Solutions' parent company, has signed a binding agreement to acquire U.S.-based...
62-year-old female patient presenting for 3D screening mammogram. Location of an indeterminate low-density circumscribed mass was not clearly determined as at the skin line or just under the surface.

62-year-old female patient presenting for 3D screening mammogram. Location of an indeterminate low-density circumscribed mass was not clearly determined as at the skin line or just under the surface.

Feature | Mammography | May 31, 2019 | By Olive Peart M.S., R.T.(R)(M)
In recent years there has been a lot of debate about the role of the...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Novel Artificial Intelligence Method Predicts Future Risk of Breast Cancer
News | Artificial Intelligence | May 08, 2019
Researchers from two major institutions have developed a new tool with advanced artificial intelligence (AI) methods to...